Kymera Therapeutics Stock Soars 50% On Strong Atopic Dermatitis Trial Results

Core Viewpoint - Kymera Therapeutics (KYMR) experienced a significant stock price increase of 38.46 percent, rising $25.62 to $92.24 following the announcement of positive clinical results from its Phase 1b BroADen trial of KT-621, an oral STAT6 degrader for atopic dermatitis [1] Stock Performance - The current trading price of Kymera is $99.84, compared to a previous close of $66.62 on the Nasdaq [1] - The stock opened at $89.47 and has fluctuated between $86.84 and $103.00 during the trading session, with a trading volume of 5,319,985 shares [1] - The 52-week stock price range for Kymera is between $19.44 and $103.00 [1]